Ultralow‐dose rituximab in pemphigus: a single‐centre experience
- 15 October 2021
- journal article
- letter
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 186 (3) , 581-583
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Long‐term outcomes of rituximab therapy in pemphigusJournal of the European Academy of Dermatology and Venereology, 2020
- Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot studyExpert Opinion on Biological Therapy, 2020
- Pemphigus: Current and Future Therapeutic StrategiesFrontiers in Immunology, 2019
- Single, very low rituximab doses in healthy volunteers - a pilot and a randomized trial: implications for dosing and biosimilarity testingScientific Reports, 2018
- First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trialThe Lancet, 2017
- Efficacy of Rituximab for Pemphigus: A Systematic Review and Meta-analysis of Different RegimensActa Dermato-Venereologica, 2015
- Low-dose rituximab is effective in pemphigusBritish Journal of Dermatology, 2011
- Consensus statement on definitions of disease, end points, and therapeutic response for pemphigusJournal of the American Academy of Dermatology, 2008